Eprobemide |
|
| Trade names | Befol (RU) |
|---|
| Other names | Befol |
|---|
Routes of administration | Oral |
|---|
|
| Legal status |
- In general: ℞ (Prescription only)
|
|---|
|
4-Chloro-N-[3-(4-morpholinyl)propyl]benzamide
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C14H19ClN2O2 |
|---|
| Molar mass | 282.77 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
C1COCCN1CCCNC(=O)C2=CC=C(C=C2)Cl
|
InChI=1S/C14H19ClN2O2/c15-13-4-2-12(3-5-13)14(18)16-6-1-7-17-8-10-19-11-9-17/h2-5H,1,6-11H2,(H,16,18) Key:YYFGRAGNYHYWEZ-UHFFFAOYSA-N
|
Eprobemide (INN) is a pharmaceutical drug that was used as an antidepressant in Russia (under the brand name Бефол/Befol).[1] It is a non-competitive reversible inhibitor of monoamine oxidase A[2][3] that exhibits selective action on serotonin deamination.[4] Eprobemide differs from moclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.[5]
See also
References
- ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Vol. 3. CRC Press. p. 811. ISBN 978-0412466304.
- ^ Gol'dina OA, Moskvitina TA, Gankina EM, Kirkel' AZ, Kamyshanskaia NS, Lopatina KI, et al. (March 1991). "[The action of befol and its derivatives on monoamine oxidase of different origins]". Biulleten' Eksperimental'noi Biologii I Meditsiny. 111 (3): 279–80. PMID 2054504.
- ^ Donskaya NS, Antonkina OA, Glukhan EN, Smirnov SK (2004-07-01). "Antidepressant Befol Synthesized Via Interaction of 4-Chloro-N-(3-chloropropyl)benzamide with Morpholine". Pharmaceutical Chemistry Journal. 0091-150X. 38 (7): 381–384. doi:10.1023/B:PHAC.0000048439.38383.5f. S2CID 29121452.
- ^ "Eprobemide". ChemIDplus.
- ^ "Befol". 4DOKTOR.RU Drug Information Handbook (in Russian). Retrieved 4 February 2014.
|
|---|
|
|---|
| SSRIsTooltip Selective serotonin reuptake inhibitors | |
|---|
| SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors | |
|---|
| NRIsTooltip Norepinephrine reuptake inhibitors | |
|---|
| NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors | |
|---|
| NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants | |
|---|
| SARIsTooltip Serotonin antagonist and reuptake inhibitors | |
|---|
| SMSTooltip Serotonin modulator and stimulators | |
|---|
| Others | |
|---|
|
|
|
|---|
| TCAsTooltip Tricyclic antidepressants | |
|---|
| TeCAsTooltip Tetracyclic antidepressants | |
|---|
| Others | |
|---|
|
|
|
|---|
| Non-selective | |
|---|
| MAOATooltip Monoamine oxidase A-selective | |
|---|
| MAOBTooltip Monoamine oxidase B-selective | |
|---|
|
|
|
|
|
|
|---|
| Non-specific | | AAADTooltip Aromatic L-amino acid decarboxylase | |
|---|
| MAOTooltip Monoamine oxidase | |
|---|
|
|---|
Phenethylamines (dopamine, epinephrine, norepinephrine) | | PAHTooltip Phenylalanine hydroxylase |
- Substrates→Products: Phenylalanine→Tyrosine
|
|---|
| THTooltip Tyrosine hydroxylase | |
|---|
| DBHTooltip Dopamine beta-hydroxylase | |
|---|
| PNMTTooltip Phenylethanolamine N-methyltransferase |
- Inhibitors: CGS-19281A
- SKF-64139
- SKF-7698
|
|---|
| COMTTooltip Catechol-O-methyl transferase | |
|---|
|
|---|
Tryptamines (serotonin, melatonin) | | TPHTooltip Tryptophan hydroxylase |
- Substrates→Products: Tryptophan→5-HTP
|
|---|
| AANATTooltip Serotonin N-acetyl transferase | |
|---|
| ASMTTooltip Acetylserotonin O-methyltransferase | |
|---|
|
|---|
| Histamine | | HDCTooltip Histidine decarboxylase |
- Substrates→Products: L-Histidine→Histamine
|
|---|
| HNMTTooltip Histamine N-methyltransferase |
- Substrates→Products: Histamine→N-Methylhistamine
|
|---|
| DAOTooltip Diamine oxidase |
- Substrates→Products: Histamine→Imidazole acetic acid
|
|---|
|
|---|
See also: Receptor/signaling modulators • Adrenergics • Dopaminergics • Melatonergics • Serotonergics • Monoamine reuptake inhibitors • Monoamine releasing agents • Monoamine neurotoxins |